OBJECTIVE: Controversy exists as to whether women with depression respond better to selective serotonin reuptake inhibitors (SSRIs) than men. The purpose of this report was to determine whether men and women differ in their responses to treatment with the SSRI citalopram using a large sample of real world patients from primary and psychiatric specialty care settings. METHOD: As part of the sequenced treatment alternatives to relieve depression (STAR *D) study, 2876 participants were treated with citalopram for up to 12-14 weeks. Baseline demographic and clinical characteristics and outcomes were gathered and compared between men and women. RESULTS: At baseline, women were younger, had more severe depressive symptoms and were more likely to have: early onset; previous suicide attempt(s); a family history of depression, alcohol abuse or drug abuse; atypical symptom features; and one or more of several concurrent psychiatric disorders. Despite greater baseline severity and more Axis I comorbidities, women were more likely to reach remission and response with citalopram than men. CONCLUSIONS: Women have a better response to the SSRI citalopram than men, which may be due to sex-specific biological differences particularly in serotonergic systems.
OBJECTIVE: Controversy exists as to whether women with depression respond better to selective serotonin reuptake inhibitors (SSRIs) than men. The purpose of this report was to determine whether men and women differ in their responses to treatment with the SSRI citalopram using a large sample of real world patients from primary and psychiatric specialty care settings. METHOD: As part of the sequenced treatment alternatives to relieve depression (STAR *D) study, 2876 participants were treated with citalopram for up to 12-14 weeks. Baseline demographic and clinical characteristics and outcomes were gathered and compared between men and women. RESULTS: At baseline, women were younger, had more severe depressive symptoms and were more likely to have: early onset; previous suicide attempt(s); a family history of depression, alcohol abuse or drug abuse; atypical symptom features; and one or more of several concurrent psychiatric disorders. Despite greater baseline severity and more Axis I comorbidities, women were more likely to reach remission and response with citalopram than men. CONCLUSIONS:Women have a better response to the SSRI citalopram than men, which may be due to sex-specific biological differences particularly in serotonergic systems.
Authors: Frederic M Quitkin; Jonathan W Stewart; Patrick J McGrath; Bonnie P Taylor; Mayra S Tisminetzky; Eva Petkova; Ying Chen; Guoguang Ma; Donald F Klein Journal: Am J Psychiatry Date: 2002-11 Impact factor: 18.112
Authors: Maurizio Fava; A John Rush; Madhukar H Trivedi; Andrew A Nierenberg; Michael E Thase; Harold A Sackeim; Frederic M Quitkin; Steven Wisniewski; Philip W Lavori; Jerrold F Rosenbaum; David J Kupfer Journal: Psychiatr Clin North Am Date: 2003-06
Authors: Malene Grubbe Hildebrandt; Ewout Willem Steyerberg; Kurt Bjerregaard Stage; Jan Passchier; Per Kragh-Soerensen Journal: Am J Psychiatry Date: 2003-09 Impact factor: 18.112
Authors: Holly A Garriock; Jeffrey B Kraft; Stanley I Shyn; Eric J Peters; Jennifer S Yokoyama; Gregory D Jenkins; Megan S Reinalda; Susan L Slager; Patrick J McGrath; Steven P Hamilton Journal: Biol Psychiatry Date: 2010-01-15 Impact factor: 13.382
Authors: Manish K Jha; Abu Minhajuddin; Cherise Chin-Fatt; Tracy L Greer; Thomas J Carmody; Madhukar H Trivedi Journal: J Psychiatr Res Date: 2019-03-20 Impact factor: 4.791
Authors: Namni Goel; Tracy L Bale; C Neill Epperson; Susan G Kornstein; Gloria R Leon; Lawrence A Palinkas; Jack W Stuster; David F Dinges Journal: J Womens Health (Larchmt) Date: 2014-09-26 Impact factor: 2.681
Authors: Arndis Simonsen; Jørgen Scheel-Krüger; Mads Jensen; Andreas Roepstorff; Arne Møller; Chris D Frith; Daniel Campbell-Meiklejohn Journal: Psychopharmacology (Berl) Date: 2014-01-25 Impact factor: 4.530
Authors: Helen P Hazuda; Sarah A Gaussoin; Rena R Wing; Susan Z Yanovski; Karen C Johnson; Mace Coday; Thomas A Wadden; Edward S Horton; Brent Van Dorsten; William C Knowler Journal: Diabetes Care Date: 2019-03-04 Impact factor: 19.112